Nordea Investment Management AB Sells 554,262 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Nordea Investment Management AB has reduced its stake in Edwards Lifesciences Corporation by 11.3%, selling 554,262 shares and now owning 4,357,428 shares valued at approximately $338.6 million.
• Several institutional investors, including Nuveen LLC and Jennison Associates LLC, have actively adjusted their positions in Edwards Lifesciences, with a significant majority of 79.46% of the stock held by institutional investors.
• Analysts have mixed sentiments on Edwards Lifesciences, with ratings ranging from "Strong Buy" to "Hold", and a projected average price target of $87.06.

Nordea Investment Management AB reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 11.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,357,428 shares of the medical research company's stock after selling 554,262 shares during the period. Nordea Investment Management AB owned about 0.74% of Edwards Lifesciences worth $338,638,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in EW. Nuveen LLC bought a new stake in Edwards Lifesciences in the first quarter valued at approximately $330,881,000. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the last quarter. Mirova US LLC boosted its holdings in Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company's stock valued at $229,257,000 after acquiring an additional 1,054,301 shares during the last quarter. Woodline Partners LP boosted its holdings in Edwards Lifesciences by 7,805.0% in the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company's stock valued at $59,822,000 after acquiring an additional 814,917 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Edwards Lifesciences by 339.7% in the first quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company's stock valued at $65,381,000 after acquiring an additional 709,648 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

EW has been the topic of several analyst reports. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the company a "buy" rating in a report on Monday, September 22nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. William Blair raised shares of Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and an average price target of $87.06.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $72.66 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The stock's 50 day moving average is $77.61 and its 200-day moving average is $76.14. The firm has a market capitalization of $42.66 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.50 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.